Manufacturing quality and continuous research and development are two fundamental pillars in the growth and advancement of Iran's vital pharmaceutical industry, and they play a crucial role in safeguarding public health and improving the community's quality of life. Without sustained investment in these areas, achieving safe, effective medicines that comply with international standards would not be possible. At Ramopharmin, we believe that producing pharmaceutical products at the highest level of quality is not only a professional responsibility but also an ethical commitment to public health. Therefore, by relying on modern technologies, strict adherence to international standards, and the continuous development of research processes, we remain committed to advancing the pharmaceutical industry and improving the health of our fellow citizens.

Ramopharmin Pharmaceutical Company was registered on 1348/02/24 (in the Iranian calendar) under number 13150 at the Tehran Companies Registration Office. The company was initially established as a limited liability company, and subsequently, based on the notice published in Official Gazette No. 10372 dated 1359/07/13, it was converted into a private joint-stock company. In Aban 1403 (in the Iranian calendar), with the aim of growth and quality improvement, the company was officially transferred to the private sector and came under the ownership of the KheshT Investment Group. As a long-established brand, Ramopharmin is proud to be one of the country's reputable manufacturers of tablets, capsules, syrups, and drops. Among these products are medicines such as azathioprine, hyoscine, lactulose, levodopa-carbidopa, carbamazepine, lithium, gabapentin, fenofibrate, chlordiazepoxide, pregabalin, and more.